Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 24, 2025 07:30 ET | Source: Alumis Inc.

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in 3Q 2026